Kate Khair1, Debra Pollard2, Catherine Harrison3, Susan Hook4, Mike O'Driscoll5, Michael Holland6. 1. The Centre for Outcomes and Experience Research in Children's Health, Illness and Disability (ORCHID), Great Ormond Street Hospital for Children, London, UK. 2. The KD Haemophilia Centre & Thrombosis Unit, Royal Free Hampstead NHS Trust, London, UK. 3. Haemophilia & Thrombosis Centre/P100, Royal Hallamshire Hospital, Sheffield, UK. 4. Royal Edinburgh Infirmary, Edinburgh, UK. 5. School of Health and Education, Middlesex University, London, UK. 6. Haemnet, London, UK.
Abstract
INTRODUCTION: Extended half-life (EHL) clotting factors have been shown to offer people with haemophilia (PwH) protection from bleeding with fewer infusions, which might reduce treatment burden. AIM: The HOw Patients view Extended half-life products (HOPE) study aimed to explore, understand and describe patient expectations around the prophylactic use of EHL products and to establish whether these expectations were met through individual follow-up analysis. METHODS: The HOPE study was a prospective, qualitative cohort study conducted among PwH who had switched to Fc fusion protein EHL products in routine clinical care and who had not been recruited to clinical trials of these products. Semi-structured audio-recorded interviews were undertaken over two time points; transcripts were analysed to systematically generate theory from data that contains both inductive and deductive thinking. RESULTS: Forty-three interviews were conducted with 25 participants. Most participants were positive about EHL treatment and intended to continue using them. Reduced frequency of infusions meant lives were less disrupted or dominated by haemophilia, and there was less perceived stress on overused veins. For those PwH who did not reduce infusion frequency, there were other perceived benefits from EHLs with respect to greater protection with higher trough levels and fewer bleeds. CONCLUSION: Patients switching to EHL treatments believe these products will result in fewer infusions and less disruption of everyday life, leaving them feeling more protected with fewer bleeds and increased activity levels, as well as enhanced well-being and mental health. Understanding patient expectation and experience around using products adds real-world data to clinical trial experience.
INTRODUCTION: Extended half-life (EHL) clotting factors have been shown to offer people with haemophilia (PwH) protection from bleeding with fewer infusions, which might reduce treatment burden. AIM: The HOw Patients view Extended half-life products (HOPE) study aimed to explore, understand and describe patient expectations around the prophylactic use of EHL products and to establish whether these expectations were met through individual follow-up analysis. METHODS: The HOPE study was a prospective, qualitative cohort study conducted among PwH who had switched to Fc fusion protein EHL products in routine clinical care and who had not been recruited to clinical trials of these products. Semi-structured audio-recorded interviews were undertaken over two time points; transcripts were analysed to systematically generate theory from data that contains both inductive and deductive thinking. RESULTS: Forty-three interviews were conducted with 25 participants. Most participants were positive about EHL treatment and intended to continue using them. Reduced frequency of infusions meant lives were less disrupted or dominated by haemophilia, and there was less perceived stress on overused veins. For those PwH who did not reduce infusion frequency, there were other perceived benefits from EHLs with respect to greater protection with higher trough levels and fewer bleeds. CONCLUSION:Patients switching to EHL treatments believe these products will result in fewer infusions and less disruption of everyday life, leaving them feeling more protected with fewer bleeds and increased activity levels, as well as enhanced well-being and mental health. Understanding patient expectation and experience around using products adds real-world data to clinical trial experience.
Authors: Karen Beny; Benjamin du Sartz de Vigneulles; Valerie Chamouard; Ronald Guilloux; Valérie Gay; Claude Negrier; Claude Dussart Journal: Patient Prefer Adherence Date: 2021-08-18 Impact factor: 2.711
Authors: Mairead O'Donovan; Eimear Quinn; Kate Johnston; Evelyn Singleton; Julie Benson; Brian O'Mahony; Declan Noone; Cleona Duggan; Ruth Gilmore; Kevin Ryan; James S O'Donnell; Niamh M O'Connell; Johnny Mahlangu Journal: Res Pract Thromb Haemost Date: 2021-10-11
Authors: Cihan Ay; Clemens Feistritzer; Joachim Rettl; Gerhard Schuster; Anna Vavrovsky; Leonard Perschy; Ingrid Pabinger Journal: Sci Rep Date: 2021-06-21 Impact factor: 4.379
Authors: Karen Beny; Benjamin du Sartz de Vigneulles; Florence Carrouel; Denis Bourgeois; Valérie Gay; Claude Negrier; Claude Dussart Journal: Int J Environ Res Public Health Date: 2022-01-06 Impact factor: 3.390